Cargando…
The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Research Institute of Tuberculosis and Lung Disease
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210576/ https://www.ncbi.nlm.nih.gov/pubmed/32411265 |
_version_ | 1783531302181404672 |
---|---|
author | Sharif-Kashani, Babak Ghanbari Motlagh, Ali Mafi, Ahmad R Esnaashari, Omid Ramzi, Mani Taghizadeh, Ali Najafi, Safa |
author_facet | Sharif-Kashani, Babak Ghanbari Motlagh, Ali Mafi, Ahmad R Esnaashari, Omid Ramzi, Mani Taghizadeh, Ali Najafi, Safa |
author_sort | Sharif-Kashani, Babak |
collection | PubMed |
description | BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective cohort study was conducted on patients with breast cancer, initiating an outpatient chemotherapy regimen in five medical centers in Iran. Eligible patients were enrolled in the study consecutively between January 2013 and January 2015. The primary outcome was lower extremity DVT based on duplex/doppler ultrasonography two months after the first course of chemotherapy (visit 2) and after the end of the course (visit 3). All patients were followed-up from the onset of chemotherapy until the first occurrence of lower extremity DVT, death, or the end of the course. RESULTS: A total of 427 eligible breast cancer patients were recruited in the study, 403 of whom attended at least one follow-up visit. The mean (SD) duration of follow-up was 4 (1.3) months. During the follow-up, only one patient showed DVT on duplex/doppler ultrasonography in visit 2. Therefore, the two-month and overall cumulative incidence risk of DVT was 0.25% (95% CI: 0.00–0.74%). However, the mean D-dimer level showed no significant change (P>0.05). CONCLUSION: Our findings showed the low risk of DVT in breast cancer patients receiving outpatient cancer therapy. |
format | Online Article Text |
id | pubmed-7210576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | National Research Institute of Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-72105762020-05-14 The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran Sharif-Kashani, Babak Ghanbari Motlagh, Ali Mafi, Ahmad R Esnaashari, Omid Ramzi, Mani Taghizadeh, Ali Najafi, Safa Tanaffos Original Article BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective cohort study was conducted on patients with breast cancer, initiating an outpatient chemotherapy regimen in five medical centers in Iran. Eligible patients were enrolled in the study consecutively between January 2013 and January 2015. The primary outcome was lower extremity DVT based on duplex/doppler ultrasonography two months after the first course of chemotherapy (visit 2) and after the end of the course (visit 3). All patients were followed-up from the onset of chemotherapy until the first occurrence of lower extremity DVT, death, or the end of the course. RESULTS: A total of 427 eligible breast cancer patients were recruited in the study, 403 of whom attended at least one follow-up visit. The mean (SD) duration of follow-up was 4 (1.3) months. During the follow-up, only one patient showed DVT on duplex/doppler ultrasonography in visit 2. Therefore, the two-month and overall cumulative incidence risk of DVT was 0.25% (95% CI: 0.00–0.74%). However, the mean D-dimer level showed no significant change (P>0.05). CONCLUSION: Our findings showed the low risk of DVT in breast cancer patients receiving outpatient cancer therapy. National Research Institute of Tuberculosis and Lung Disease 2019-03 /pmc/articles/PMC7210576/ /pubmed/32411265 Text en Copyright© 2019 National Research Institute of Tuberculosis and Lung Disease http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Sharif-Kashani, Babak Ghanbari Motlagh, Ali Mafi, Ahmad R Esnaashari, Omid Ramzi, Mani Taghizadeh, Ali Najafi, Safa The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title | The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title_full | The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title_fullStr | The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title_full_unstemmed | The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title_short | The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran |
title_sort | incidence of deep vein thrombosis in breast cancer patients receiving outpatient cancer therapy in iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210576/ https://www.ncbi.nlm.nih.gov/pubmed/32411265 |
work_keys_str_mv | AT sharifkashanibabak theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT ghanbarimotlaghali theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT mafiahmadr theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT esnaashariomid theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT ramzimani theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT taghizadehali theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT najafisafa theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT sharifkashanibabak incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT ghanbarimotlaghali incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT mafiahmadr incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT esnaashariomid incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT ramzimani incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT taghizadehali incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran AT najafisafa incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran |